Transcatheter Aortic Valve Implantation for Severe Aortic Insufficiency Due to Infective Endocarditis in a Patient with Cirrhosis and Hepatocellular Cancer: A Novel Indication

Infective endocarditis (IE) of the native aortic valve (AV) secondary to <i>Streptococcus infantarius</i> is subacute, a highly destructive pathology leading to aortic regurgitation (AR) and severe cardiac complications such as progressively deteriorating heart failure. In these cases, valvular correction with surgery may not be the optimal option because of multiple chronic illnesses and the use of medications. Although transcatheter AV implantation (TAVI) is a well-known, established alternative method to surgical replacement in patients with severe aortic stenosis, it can be a good alternative in patients with severe AR in whom valvular surgery is not an option due to comorbidities. Here, we presented a case of TAVI in a patient with cirrhosis, hepatocellular cancer, and symptomatic severe AR due to <i>S. infantarius</i> IE.